Thumbnail

アジア太平洋地域の黒色腫の診断および治療薬市場-がんおよび地域の種類別セグメント(2020年-2025年)

Looking to buy the report?

1. Introduction                                                 

                1.1 Report description                                  

                1.2 Research methodology                                         

2. Executive summary                                                  

3. Market overview                                                       

                3.1 Market definition                                    

                3.2 Market drivers                                          

                                3.2.1 Increasing incidences of melanoma cases                 

                                3.2.2 The approval and uptake of premium-priced products                        

                                3.2.3 Effective immunotherapies                             

                                3.2.4 Label extension of current therapies into the new settings                               

                                3.2.5 Government initiatives                      

                3.3 Market restraints                                     

                                3.3.1 Lack of awareness in some developing regions                       

                                3.3.2 High cost associated with the therapy                         

                                3.3.3 Economic crisis                      

                                3.3.4 Regulatory issues                 

                3.4 Market opportunities                                          

                3.5 Market threats                                         

4. Porter’s five force analysis                                                    

                4.1 Bargaining power of suppliers                                            

                4.2 Bargaining power of buyers                                

                4.3 Degree of competition                                          

                4.4 Threat of substitution                                            

                4.5 Threat of new entrants                                         

5. Market segmentation                                                              

                5.1 By cancer type                                         

                                5.1.1 Superficial spreading melanoma                    

                                5.1.2 Nodular melanoma                             

                                5.1.3 Lentigno maligna melanoma                           

                                5.1.4 Acral lentiginous melanoma                            

                                5.1.5 Amelanotic melanoma                       

                                5.1.6 Others                      

                                                5.1.6.1 Cutaneous malignant melanoma               

                                                5.1.6.2 Melanoma of vulva          

                                                5.1.6.3 Vaginal melanoma or melanoma of black passage             

                5.2 By cancer stage                                        

                                5.2.1 Stage 0                      

                                5.2.1 Stage I                       

                                5.2.1 Stage II                     

                                5.2.1 Stage III                    

                                5.2.1 Stage IV                    

                5.3 By diagnosis                                               

                                5.3.1 Dermatoscopy                       

                                5.3.2 Sentinel lymph node biopsy                            

                                5.3.3 Blood Tests                             

                                5.3.4 X-rays                        

                                5.3.5 Ultrasound                              

                                5.3.6 CT Scan                     

                5.4 By treatment                                           

                                5.4.1 For early melanoma                            

                                                5.4.1.1 Surgery 

                                                                5.4.1.1.1 Excision

                                                                5.4.1.1.2 Mohs surgery

                                5.4.2 For advanced melanoma                  

                                                5.4.2.1 Chemotherapy  

                                                5.4.2.2 Biological therapy             

                                                5.4.2.3 Radiotherapy     

                                                5.4.2.4 Targeted therapy            

                                                5.4.2.5 Immune therapy              

                                                5.4.2.6 Surgery 

                                                                5.4.2.6.1 Lymphadenectomy

                5.5 By geography                                           

                                5.5.1 Asia-Pacific          

                                                5.5.1.1 India       

                                                5.5.1.2 China     

                                                5.5.1.3 Japan     

                                                5.5.1.4 Singapore            

                                                5.5.1.5 Rest of Asia-Pacific           

6. Competitive landscape                                                           

7. Company profiles                                                       

                7.1 Abbott Diagnostics                                  

                7.2 Agilent Technologies                                              

                7.3 Roche                                           

                7.4 GlaxoSmithKline                                       

                7.5 AstraZeneca                                               

                7.6 Bristol-Myers Squibb                                              

                7.7 Eli Lilly                                           

                7.8 Merck                                           

                7.9 Novartis                                       

                7.10 Pfizer                                          

                7.11 Sanofi                                         

                7.12 Qiagen N.V. Company                                         

                7.13 Teva Pharmaceuticals                                          

8. Appendix                                                       

                8.1 Abbreviations                                             

                8.3 Bibliography                                               

                8.4 Disclaimer              

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?

Email

Message

By submitting, you confirm that you agree to our privacy policy